(KURA) Kura Oncology - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US50127T1097
KURA: Cancer, Leukemia, Solid Tumors, Head, Neck, Squamous Cell Carcinoma
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. The companys pipeline focuses on small molecule therapeutics targeting specific cancer pathways. Its lead candidates include ziftomenib, an oral menin-KMT2A inhibitor for genetically defined acute leukemias; tipifarnib, a farnesyl transferase inhibitor being tested in combination with alpelisib for PIK3CA-dependent HNSCC; and KO-2806, another farnesyl transferase inhibitor for solid tumors. Collaborations with Novartis and Kyowa Kirin enhance its development and commercialization efforts. Founded in 2014, Kura Oncology is headquartered in San Diego, California.
Based on the provided data, the 3-month forecast indicates potential volatility. Technically, the stock is below its 20 and 50-day SMAs, suggesting a bearish trend, though the ATR indicates moderate price movement. Fundamentally, with a negative ROE and no earnings, the stock may underperform unless positive clinical trial results or partnerships emerge. Short-term, expect possible volatility with a slight rebound chance, but overall bearish sentiment may persist.
Additional Sources for KURA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
KURA Stock Overview
| Market Cap in USD | 622m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2015-09-22 |
KURA Stock Ratings
| Growth 5y | -30.9% |
| Fundamental | -11.2% |
| Dividend | 0.0% |
| Rel. Strength Industry | -64.8 |
| Analysts | 4.56/5 |
| Fair Price Momentum | 5.54 USD |
| Fair Price DCF | 16.26 USD |
KURA Dividends
No Dividends PaidKURA Growth Ratios
| Growth Correlation 3m | -61.1% |
| Growth Correlation 12m | -86.6% |
| Growth Correlation 5y | -38.2% |
| CAGR 5y | -0.90% |
| CAGR/Max DD 5y | -0.01 |
| Sharpe Ratio 12m | -1.92 |
| Alpha | -82.28 |
| Beta | 1.63 |
| Volatility | 58.92% |
| Current Volume | 1535.9k |
| Average Volume 20d | 1217.3k |
As of March 15, 2025, the stock is trading at USD 7.14 with a total of 1,535,925 shares traded.
Over the past week, the price has changed by -5.18%, over one month by -13.77%, over three months by -28.42% and over the past year by -67.52%.
Neither. Based on ValueRay Fundamental Analyses, Kura Oncology is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -11.18 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KURA as of March 2025 is 5.54. This means that KURA is currently overvalued and has a potential downside of -22.41%.
Kura Oncology has received a consensus analysts rating of 4.56. Therefor, it is recommend to buy KURA.
- Strong Buy: 11
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, KURA Kura Oncology will be worth about 6.3 in March 2026. The stock is currently trading at 7.14. This means that the stock has a potential downside of -12.04%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 26.7 | 273.8% |
| Analysts Target Price | 28.4 | 297.2% |
| ValueRay Target Price | 6.3 | -12% |